SYROS PHARMACEUTICALS INC's ticker is and the CUSIP is 87184Q206. A total of 71 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $14,189,009 | -3.6% | 2,749,808 | 0.0% | 1.56% | +31.8% |
| Q1 2024 | $14,711,473 | -31.3% | 2,749,808 | 0.0% | 1.18% | -42.4% |
| Q4 2023 | $21,421,004 | +155.2% | 2,749,808 | +29.4% | 2.05% | +118.6% |
| Q3 2023 | $8,392,541 | +25.4% | 2,124,694 | 0.0% | 0.94% | +36.3% |
| Q2 2023 | $6,692,786 | +117876.1% | 2,124,694 | 0.0% | 0.69% | -2.8% |
| Q1 2023 | $5,673 | -25.6% | 2,124,694 | 0.0% | 0.71% | -16.8% |
| Q4 2022 | $7,628 | -99.9% | 2,124,694 | +96.3% | 0.85% | +2.4% |
| Q3 2022 | $6,971,000 | – | 1,082,404 | – | 0.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 767,445 | $2,417,452 | 0.73% |
| Bain Capital Life Sciences Investors, LLC | 2,124,694 | $6,692,786 | 0.69% |
| Samsara BioCapital, LLC | 881,450 | $2,776,568 | 0.49% |
| Omega Fund Management, LLC | 251,270 | $791,500 | 0.44% |
| DAFNA Capital Management LLC | 265,878 | $837,516 | 0.23% |
| Avidity Partners Management LP | 1,464,034 | $4,611,707 | 0.16% |
| Artal Group S.A. | 1,475,744 | $4,649 | 0.14% |
| Flagship Pioneering Inc. | 993,848 | $3,130,622 | 0.14% |
| Knott David M Jr | 96,260 | $303 | 0.12% |
| 1492 Capital Management LLC | 21,744 | $68,494 | 0.04% |